Previous | Home | EndoTODAY | List | Next


[´ëÇѺ¹°­°æÀ§Àå°üÇÐȸ ¿¬¼ö°­Á Áö»óÁß°è - Activities of KLASS (Korea Laparoscopic Gastrointestial Surgery Study Group)]

ÀϽÃ: 2013³â 4¿ù 25ÀÏ (¸ñ)

Àå¼Ò: È£ÅÚ ÀÎÅÍºÒ°í ´ë±¸

1. KLASS-01 (Á¶±âÀ§¾Ï º¹°­°æ°ú ¼ö¼ú ¼ö¼ú ºñ±³¿¬±¸. PI: ¼­¿ï´ëÇб³ ±èÇüÈ£)

- 5 year survivalÀ» º¸±â À§ÇÑ phase III ¿¬±¸·Î¼­ enrollment(laparoscopic 704¿¹, open 711¿¹)´Â ³¡³­ »óÅÂÀÌ°í 2015³â ÃÖÁ¾ °á°ú¸¦ ¹ßÇ¥ÇÒ ¿¹Á¤

- KLASS-01°ú °ü·ÃÇÏ¿© ÀÌ¹Ì 9°³ SCI ¿¬±¸°¡ ¹ßÇ¥µÊ


2. KLASS-02 (Prospective randomized laparoscopic subtotal gastrectomy trial for AGC, PI: ¾ÆÁÖ´ëÇб³ ÇÑ»ó¿í)

- Primary outcome: 3 year disease free survival

- Secondary outcome: early or late postoperative complications, mortalities, postoperative recovery index, postoperative quality of life, 3 year overall survival

- Ư¡: D2 dissection ¿©ºÎ¸¦ °ËÁõÇϱâ À§ÇÑ ºñµð¿À ½É»ç¸¦ Æ÷ÇÔÇÏ°í ÀÖÀ½ (10¸í¸¶´Ù ºñµð¿À Á¦Ãâ, ¸ðµç ȯÀÚ »çÁøÀ» ³²±âµµ·Ï)

- 1,050¸í(expected evetn: 330)À» ¸ñÇ¥·Î 2011³â 10¿ù µî·ÏÀ» ½ÃÀÛÇÏ¿´°í 2013³â 4¿ù±îÁö 388¸íÀÌ µî·ÏµÇ¾úÀ½.


3. KLASS-03 (Postoperative multi-center study of laparoscopic-assited total gastrectomy for clinical stage I gastric cancer, PI: Á¶±Ô¼®, ±èÁøÁ¶)

- º¹°­°æ TG(total gastrectomy)°¡ °³º¹ TG¿¡ ºñÇÏ¿© ÇÕº´ÁõÀÇ ºóµµ°¡ ÀûÀ¸¸ç ÃâÇ÷ÀÌ ÀÛÀ½ (ÃÖ±Ù metaanalysis: Hoverkamp L. Surg Endosc 2013 Dc 14)

- ½ÇÁ¦ º¹°­°æ TGÀÇ ÈÄÇâÀû ¿¬±¸°á°ú°¡ ÁÁÀ½¿¡µµ ºÒ±¸ÇÏ°í »ç¿ëºóµµ°¡ ÀûÀº Á¡Àº technicalÇÑ Ãø¸éÀÌ °ü¿©µÈ °ÍÀ¸·Î »ý°¢µÊ.

- Primary outcome (single arm study): ¼ö¼ú Àü 1±â·Î Áø´ÜµÈ »óºÎ À§¾Ï ȯÀÚ¿¡°Ô º¹°­°æÇÏ À§ÀüÀýÁ¦¼ú ÈÄ Àç°Ç¼ú ¹× ¸²ÇÁÀý ÀýÁ¦¼ú ÈÄÀÇ ÇÕº´Áõ À¯º´À² ¹× »ç¸Á·üÀÌ ±âÁ¸ÀÇ °³º¹ÇÏ À§ÀüÀýÁ¦¼úÀÇ ÇÕº´Áõ À¯º´·ü°ú »ç¸Á·ü¿¡ ºñÇÏ¿©(non-inferiority)ÇÔÀ» ¾Ë¾Æº¸´Â °Í

- Secodary outcome: ¹®ÇÕ¹æ¹ý¿¡ µû¸¥ ¼ö¼ú°á°úÀÇ Â÷ÀÌ


4. COACT 1001 (¹«ÀÛÀ§ ºñ±³¿¬±¸·Î ÁøÇ༺À§¾ÏÀÇ D2 °¡¿ë¼ºÀ» °ËÁõÇϱâ À§ÇÑ ´Ù±â°ü ¿¬±¸, PI: ±¹¸³¾Ï¼¾ÅÍ ±è¿µ¿ì)

- Feasibility of laparoscopic lymph node dissection

- Noncompliance rate´Â overallÇÏ°Ô º¹°­°æ 53%, °³º¹ 57%·Î Â÷ÀÌ°¡ ¾ø¾ú´Ù. ±×·¯³ª stage III¿¡¼­´Â º¹°­°æ 48%, °³º¹ 75%·Î ÀǹÌÀÖ´Â Â÷ÀÌ°¡ ÀÖ¾ú´Ù (p=0.0043).

- COACT 1001ÀÇ ÀǹÌ: Pivoting trial for rationale of laparoscopic gastrectomy of AGC

- New study Á¦¾È: COACT 1301 (ADDCIT) (Assessment of D1+ vs D2 distal and total gastrectomy for clinical stage IB & II gastric cacner, PI: ±¹¸³¾Ï¼¾ÅÍ ±è¿µ¿ì): ÃæºÐÇÑ event°¡ Ã߽à ±â°£ Áß¿¡ ¹ß»ýÇÏ¿©¾ß Çϱ⠶§¹®¿¡ non-inferity marginÀ» ÃæºÐÈ÷ °í·ÁÇÑ °á°ú 1,880¸íÀÇ Å« sample size°¡ ÇÊ¿äÇÑ ¿¬±¸·Î ´Ù±â°ü ¿¬±¸°¡ ÇʼöÀûÀ̸ç, ¼ö¼úÀÇ Ç¥ÁØÈ­°¡ ¿¬±¸ ¼º°øÀÇ ÃÖ´ëÀÇ °ü°ÇÀÌ µÇ¹Ç·Î ÇöÀç È°¹ßÇÑ ¼ö¼ú ºñµð¿À ¼¼¹Ì³ª°¡ ÁøÇà ÁßÀÌ´Ù.


5. Multi-institutional study on the assessment of robotic surgery for gastric cancer (PI: ¿¬¼¼´ëÇб³ Çü¿ìÁø)

- º¸°Çº¹Áöº¹ ¾ÏÁ¤º¹°úÁ¦ ¿¬±¸ºñ Áö¿ø

- 18º´¿ø 30¸í ¿¬±¸ÀÚ°¡ Âü¿©ÇÑ nonrandomized comparison (·Îº¿¼ö¼úÀÌ ³Ê¹« °í°¡À̹ǷΠÀü ºñ¿ëÀ» ¿¬±¸ºñ·Î °¨´çÇÒ ¼ö ¾ø±â ¶§¹®¿¡ ¹«ÀÛÀ§ ¿¬±¸°¡ ¾î·Á¿ò)

- 5°³ ¼¼ºÎ°úÁ¦: 1) Registration of all robotic gastrectomies performed in Korea, 2) ÇнÀ°î¼±, 3) »îÀÇ Áú, 4) ºñ¿ë È¿°ú, 5) acute inflammatory response

- Retrospective cohort: 1,043¸í

- Prospective cohort: 2012³â 12¿ù ÀüÇâÀûÀ¸·Î ·Îº¿ 223¸í, º¹°­°æ 211¸í µî·ÏÀ» ¸¶Ä§


6. SENORITA (Sentinel node oriented tailored approach, PI: ±¹¸³¾Ï¼¾ÅÍ ·ù±Ù¿ø)

- 17°³ ±â°ü

- Primary end point: 3 year disease free survival

- Seconday end point: postoperative morbidity, mortality, QoL

- The expected 3yDFS of the control group is 97% and the non-inferior margin is defined 92% with hazard ration 1.0 with confidence interval upper limit 2.737.

- Tracers: 99mTc-human serum albumin (2ml, 0.1Ci/ml) + IGC (2 ml)À» ¼ö¼úÁß¿¡ ³»½Ã°æÀ¸·Î simultaneous submucosal 4 sites injection

- Primary tumor resection

MucoalMucosalSubmucosalSubmucosal
<=2020< <=30<=2020< <=30
DiffExclusionESD
(LWR,EFTR)
(Segmental)
LWR,EFTR
(Segmental)
Segmental
UndiffESD
(LWR,EFTR)
(Segmental)
SegmentalLWR,EFTR
(Segmental)
Segmental


7. Comments

- Floor comment: Noninferiority study¿¡ ¸Ó¹°°í ÀÖ´Ù´Â Á¡ÀÌ ¾Æ½±´Ù.

- ÁÂÀå comment: ¸ðµç ¿¬±¸´Â Ç×»ó ethical boundary ¾È¿¡ ÀÖ¾î¾ß ÇÏ°Ú´Ù.

[Home]